THE DISORDER OF DIASTOLIC FUNCTION OF HEART UNDER FIBRILLATION OF ATRIA


如何引用文章

全文:

详细

In spite of significant increasing of number of patients with disorders of diastolic function of heart and fibrillation of atria, understanding of mechanisms of their development and modes of treatment is still to be reached. The present review presents Actual view of the role of diastolic dysfunction of heart in development and progression of fibrillation of atria, including possibilities of its adjustment after interventional treatment.

作者简介

A. Baymukhanov

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

Email: baymukanov@gmail.com
post-graduate student of the chair of hospital therapy №2 of the N.I. Pirogov Russian national research medical university, 117997, Mosсow, Russian Federation 117997, Moscow, Russian Federation

I. Khamnagadaev

The research clinical institute of pediatrics of the N.I. Pirogov Russian national research medical university Minzdrav of Russia; The V.M. Buianov municipal clinical hospital of the Moscow Health department

117997, Moscow, Russian Federation; 115516 ,Moscow, Russian Federation

G. Gendlin

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

117997, Moscow, Russian Federation

I. Nikitin

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

117997, Moscow, Russian Federation

参考

  1. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. 1982; 306 (17): 1018-22.
  2. Zoni-Berisso M., Lercari F., Carazza T., Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin. Epidemiol. 2014; (6): 213-20.
  3. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J. et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014; 129 (8): 837-47.
  4. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370-5.
  5. Колбин А.С., Татарский Б.А., Бисерова И.Н., Загородникова К.А., Балыкина Ю.Е., Проскурин М.А. и др. Социально-экономическое бремя мерцательной аритмии в Российской Федерации. Клиническая фармакология и терапия. 2010; 19 (4): 17-22
  6. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockolm Cohort of Atrial Fibrillation. Eur. Heart J. 2010; 31 (8): 967-72.
  7. Ho J.E., Lyass A., Lee D.S., Vasan R.S., Kannel W.B., Larson M.G. et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection. Circ. Heart Fail. 2013; 6 (2): 279-86.
  8. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 2005; 352 (3): 225-37.
  9. Kadish A., Dyer A., Daubert J.P., Quigg R., Estes N.A., Anderson K.P. et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. 2004; 350 (21): 2151-8.
  10. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362 (9386): 767-71.
  11. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008; 359 (23): 2456-67.
  12. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino R. Jr., Ferdinand K. et al. Combination of isosorbidedinitrate and hydralazine in HF blacks with heart failure. N. Engl. J. Med. 2004; 351 (20): 2049-57.
  13. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364 (1): 11-21.
  14. Køber L., Torp-Pedersen C., McMurray J.J., Gøtzsche O., Lévy S., Crijns H. et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 2008; 358 (25): 2678-87.
  15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316 (23): 1429-35.
  16. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J. Am. Coll. Cardiol. 1998; 32 (3): 695-703.
  17. Zile M.R., Gaasch W.H., Carroll J.D., Feldman M.D., Aurigemma G.P., Schaer G.L. et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001; 104 (7): 779-82.
  18. Dougherty A.H., Naccarelli G.V., Gray E.L., Hicks C.H., Goldstein R.A. Congestive heart failure with normal systolic function. Am. J. Cardiol. 1984; 54 (7): 778-82.
  19. LeWinter M.M, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it’s not one thing it’s another. Circ. Heart. Fail. 2013; 6 (6): 1112-5.
  20. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная недостаточность. 2004; 5 (1): 4-7
  21. Rosenberg M.A., Manning W.J. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation. 2012; 126 (19): 2353-62.
  22. Lee D.S., Gona P., Vasan R.S., Larson M.G., Benjamin E.J., Wang T.J. et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009; 119 (24): 3070-7.
  23. Tedrow U.B., Conen D., Ridker P.M., Cook N.R., Koplan B.A., Manson J.E. et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women’s Health Study). J. Am. Coll. Cardiol. 2010; 55 (21): 2319-27.
  24. Patil V.C., Patil H.V., Shah K.B., Vasani J.D., Shetty P.Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J. Cardiovasc. Dis. Res. 2011; 2 (4): 213-22.
  25. Tsang T.S., Gersh B.J., Appleton C.P., Tajik A.J., Barnes M.E., Bailey K.R. et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol. 2002; 40 (9): 1636-44.
  26. Calkins H., el-Atassi R., Kalbfleisch S., Langberg J., Morady F. Effects of an acute increase in atrial pressure on atrial refractoriness in humans. Pacing Clin. Electrophysiol. 1992; 15 (11, Pt. 1): 1674-80.
  27. Nattel S., Shiroshita-Takeshita A., Brundel B.J., Rivard L. Mechanisms of atrial fibrillation: lessons from animal models. Prog. Cardiovasc. Dis. 2005; 48 (1): 9-28.
  28. Nattel S., Maguy A., Le Bouter S., Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 2007; 87 (2): 425-56.
  29. Nattel S., Li D., Yue L. Basic mechanisms of atrial fibrillation-very new insights into very old ideas. Annu. Rev. Physiol. 2000; 62: 51-77.
  30. Hanna N., Cardin S., Leung T., Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc. Res. 2004; 63 (2): 236-44.
  31. Schotten U., Neuberger H.R., Allessie M.A. The role of atrial dilatation in the domestication of atrial fibrillation. Prog. Biophys. Mol. Biol. 2003; 82 (1-3): 151-62.
  32. Rosenberg M.A., Gottdiener J.S., Heckbert S.R., Mukamal K.J. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur. Heart J. 2012; 33 (7): 904-12.
  33. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 2008; 51 (8): 802-9.
  34. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., Seward J.B. Risks for atrial fibrillation and congestive heart failure in patients >/= 65 years of age with abnormal left ventricular diastolic relaxation. Am. J. Cardiol. 2004; 93 (1): 54-8.
  35. Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F. 3rd, Dokainish H., Edvardsen T. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016; 29 (4): 277-314.
  36. Агеев Ф.Т., Овчинников А.Г. Давление наполнения левого желудочка: механизмы развития и ультразвуковая оценка. Сердечная недостаточность. 2012; 13 (5): 287-309
  37. Yamamoto K., Redfield M.M., Nishimura R.A. Analysis of left ventricular diastolic function. Heart. 1996; (75): 27-35
  38. Васюк Ю.А., Хадзегова А.Б., Иванова С.В., Ющук Е.Н., Амирбегишвили И.М., Герасимова Н.И. Тканевая допплерография в ранней диагностике функциональных нарушений миокарда при артериальной гипертензии. Рациональная фармакотерапия в кардиологии. 2008; 4 (1): 39-43
  39. Jeong E., Dudley S. Diastolic dysfunction. Circ. J. 2015; 79 (3): 470-7.
  40. Kadappu K.K., Thomas L. Tissue Doppler imaging in echocardiography: value and limitations. Heart Lung Circ. 2015; 24 (3): 224-33.
  41. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., Seward J.B. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am. J. Cardiol. 2002; 90 (12): 1284-9.
  42. Keren G., Sherez J., Megidish R., Levitt B., Laniado S. Pulmonary venous flow pattern-its relation ship to cardiac dynamics: apulsed Doppler echocardiographic study. Circulation. 1985; 71 (6): 1105-12.
  43. Apostolakis S., Konstantinides S. The right ventricle in health and disease: insights into physiology, pathophysiology and diagnostic management. Cardiology. 2012; 121 (4): 263-73.
  44. Chakko S., de Marchena E., Kessler K.M., Materson B.J., Myerburg R.J. Right ventricular diastolic function in systemic hypertension. Am. J. Cardiol. 1990; 65 (16): 1117-20.
  45. Kukulski T., Hübbert L., Arnold M., Wranne B., Hatle L., Sutherland G.R. Normal regional right ventricular function and its change with age: a Doppler myocardial imaging study. J. Am. Soc. Echocardiogr. 2000; 13 (3): 194-204.
  46. Sade L.E., Gulmez O., Eroglu S., Sezgin A., Muderrisoglu H. Noninvasive estimation of right ventricular filling pressure by ratio of early tricuspid inflow to annular diastolic velocity in patients with and without recent cardiac surgery. Am. Soc. Echocardiogr. 2007; 20 (8): 982-8.
  47. Zakeri R., Mohammed S.F. Epidemiology of Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction. Curr. Heart Fail. Rep. 2015; 12 (5): 295-301.
  48. Melenovsky V., Hwang S.J., Lin G., Redfield M.M., Borlaug B.A. Right heart dysfunction in heart failure with preserved ejection fraction. Eur. Heart J. 2014; 35 (48): 3452-62.
  49. Chen H.H., Lainchbury J.G., Senni M., Bailey K.R., Redfield M.M.Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J. Card. Fail. 2002; 8 (5): 279-87.
  50. Zakeri R., Borlaug B.A., McNulty S.E., Mohammed S.F., Lewis G.D., Semigran M.J. et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ. Heart Fail. 2014; 7 (1): 123-30.
  51. Wilber D.J., Pappone C., Neuzil P., De Paola A., Marchlinski F., Natale A. et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010; 303 (4): 333-40.
  52. Cosedis Nielsen J., Johannessen A., Raatikainen P., Hindricks G., Walfridsson H., Kongstad O. et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N. Engl. J. Med. 2012; 367 (17): 1587-95.
  53. Haïssaguerre M., Jaïs P., Shah D.C., Takahashi A., Hocini M., Quiniou G. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998; 339 (10): 659-66.
  54. Bunch T.J., Cutler M.J. Is pulmonary vein isolation still the cornerstone in atrial fibrillation ablation? J. Thorac. Dis. 2015; 7 (2): 132-41.
  55. Ang R., Earley M.J. The role of catheter ablation in the management of atrial fibrillation. Clin. Med. (Lond.). 2016; 16 (3): 267-71.
  56. January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. Jr. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130 (23): e199-e267.
  57. Jaïs P., Cauchemez B., Macle L., Daoud E., Khairy P., Subbiah R. et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 Study. Circulation. 2008; 118 (24): 2498-505.
  58. Packer D.L., Kowal R.C., Wheelan K.R., Irwin J.M., Champagne J., Guerra P.G. et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J. Am. Coll. Cardiol. 2013; 61 (16): 1713-23.
  59. Kuck K.H., Brugada J., Fürnkranz A., Metzner A., Ouyang F., Chun K.R. et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N. Engl. J. Med. 2016; 374 (23): 2235-45.
  60. Nedios S., Sommer P., Dagres N., Kosiuk J., Arya A., Richter S. et al. Long-termfollow-up after atrial fibrillation ablation in patients with impaired left ventricular systolic function: the importance of rhythm and rate control. Heart Rhythm. 2014; 11 (3): 344-51.
  61. Machino-Ohtsuka T., Seo Y., Ishizu T., Yanaka S., Nakajima H., Atsumi A. et al. Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ. J. 2013; 77 (7): 1695-704.
  62. Santos S., Henz B., Zanatta A., Barreto J.R., Loureiro K.B., Novakoski C. et al. Impact of Atrial Fibrillation Ablation on Left Ventricular Filling Pressure and Left Atrial Remodeling. Arq. Bras. Cardiol. 2014; 103 (6): 485-92.
  63. Cha Y.M., Wokhlu A., Asirvatham S.J., Shen W.K., Friedman P.A., Munger T.M. et al. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ. Arrhythm. Electrophysiol. 2011; 4 (5): 724-32.
  64. Reant P., Lafitte S., Jaïs P.,Serri K., Weerasooriya R., Hocini M. et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005; 112 (19): 2896-903.
  65. Kim I.S., Kim T.H., Shim C.Y., Mun H.S., Uhm J.S., Joung B. et al. The ratio of early transmitral flow velocity (E) to early mitral annular velocity (Em) predicts improvement in left ventricular systolic and diastolic function 1 year after catheter ablation for atrial fibrillation. Europace. 2015; 17 (7): 1051-8.
  66. Gibson D.N., Di Biase L., Mohanty P.,Patel J.D., Bai R., Sanchez J. et al. Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors. Heart Rhythm. 2011; 8 (9): 1364-71.
  67. Wylie J.V. Jr., Peters D.C., Essebag V., Manning W.J., Josephson M.E., Hauser T.H. Left atrial function and scar after catheter ablation of atrial fibrillation. Heart Rhythm. 2008; 5 (5): 656-62.
  68. Kosiuk J., Buchta P., Gaspar T., Arya A., Piorkowski C., Rolf S. et al. Prevalence and predictors of worsened left ventricular diastolic dysfunction after catheter ablation of atrial fibrillation. Int. J. Cardiol. 2013; 168 (4): 3613-5.
  69. Matsui Y., Morimoto J., Uede T. Role of matricellular proteins in cardiac tissue remodelling after myocardial infarction. World J. Biol. Chem. 2010; 1 (5): 69-80.

版权所有 © Eco-Vector, 2017


 


##common.cookie##